- Home
- TDOC vs PCRX Comparison
TDOC vs PCRX Comparison
Compare TDOC & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDOC
- PCRX
- Stock Information
- Founded
- TDOC 2002
- PCRX 2006
- Country
- TDOC United States
- PCRX United States
- Employees
- TDOC N/A
- PCRX N/A
- Industry
- TDOC Medical/Nursing Services
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- TDOC Health Care
- PCRX Health Care
- Exchange
- TDOC Nasdaq
- PCRX Nasdaq
- Market Cap
- TDOC 1.3B
- PCRX 1.2B
- IPO Year
- TDOC 2015
- PCRX 2011
- Fundamental
- Price
- TDOC $7.11
- PCRX $25.12
- Analyst Decision
- TDOC Buy
- PCRX Buy
- Analyst Count
- TDOC 19
- PCRX 9
- Target Price
- TDOC $9.71
- PCRX $29.89
- AVG Volume (30 Days)
- TDOC 5.4M
- PCRX 745.0K
- Earning Date
- TDOC 04-30-2025
- PCRX 05-08-2025
- Dividend Yield
- TDOC N/A
- PCRX N/A
- EPS Growth
- TDOC N/A
- PCRX N/A
- EPS
- TDOC N/A
- PCRX N/A
- Revenue
- TDOC $2,552,812,000.00
- PCRX $702,772,000.00
- Revenue This Year
- TDOC N/A
- PCRX $9.48
- Revenue Next Year
- TDOC $1.60
- PCRX $11.31
- P/E Ratio
- TDOC N/A
- PCRX N/A
- Revenue Growth
- TDOC N/A
- PCRX 3.08
- 52 Week Low
- TDOC $6.35
- PCRX $11.16
- 52 Week High
- TDOC $15.21
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- TDOC 44.87
- PCRX 48.10
- Support Level
- TDOC $6.73
- PCRX $25.08
- Resistance Level
- TDOC $7.27
- PCRX $27.34
- Average True Range (ATR)
- TDOC 0.35
- PCRX 1.16
- MACD
- TDOC 0.08
- PCRX -0.18
- Stochastic Oscillator
- TDOC 55.24
- PCRX 48.85
About TDOC Teladoc Health Inc.
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.